Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Use Versus Ribavirin Dose Reduction for the Management of Anemia
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 687
- 主要终点
- Percentage of Participants With Sustained Virologic Response (SVR)
研究概览
简要总结
The current trial is designed to prospectively explore the safety of erythropoietin use for the treatment of anemia during boceprevir plus peginterferon alfa-2b/Ribavirin (PEG2b/RBV) therapy and to assess its relationship to efficacy. All participants in this trial will be treated with the triple combination of boceprevir plus PEG2b/RBV. If a participant becomes anemic during treatment, the participant will be randomized to one of two therapeutic strategies for management of anemia (erythropoietin use versus RBV dose reduction).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must have previously documented Chronic Hepatitis C (CHC) genotype 1 infection.
- •Hemoglobin concentration at Screening must be ≤15 g/dL for both females and males.
- •Participant must have a liver biopsy with histology consistent with CHC and no other etiology.
- •Participant with bridging fibrosis (F3) or cirrhosis (F4) must have an ultrasound within 6 months of the Screening Visit (or between Screening and Day 1) with no findings suspicious for hepatocellular carcinoma.
- •Participant's weight must be ≥40 kg and ≤125 kg.
- •Participant and participant's partner(s) must each agree to use acceptable methods of contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study medication, or longer if dictated by local regulations.
- •Participant must be willing to give written informed consent.
- •Participant must be willing to attend frequent site visits for the duration of the trial.
- •Participant must not have any contraindications for the use of erythropoietin.
排除标准
- •Participants known to be coinfected with the human immunodeficiency virus (HIV) or hepatitis B virus.
- •Participants who received prior treatment for hepatitis C.
- •Treatment with any investigational drug within 30 days of the screening visit in this trial.
- •Participants receiving any of the following medication(s) within 2 weeks prior to the Day 1 visit: alfuzosin, antiarrhythmics (amiodarone, bepridil, flecainide, propafenone, and quinidine), ergot derivatives, cisapride, lovastatin, simvastatin, pimozide, triazolam, and orally administered midazolam.
- •Participation in any other clinical trial within 30 days of the screening visit in this trial or intention to participate in another clinical trial during participation in this trial.
- •Evidence of decompensated liver disease.
- •Diabetic and/or hypertensive participants with clinically significant ocular examination findings.
- •Pre-existing psychiatric condition(s).
- •Clinical diagnosis of substance abuse of specified drugs within specified timeframes.
- •Any known pre-existing medical condition that could interfere with the participant's participation in and completion of the trial.
- •Evidence of active or suspected malignancy, or a history of malignancy, within the last 5 years (except adequately treated carcinoma in situ and basal cell carcinoma of the skin).
- •Participants who are pregnant or nursing. Participants who intend to become pregnant during the trial period. Male participants with partners who are, or intend to become, pregnant during the trial period.
- •Any other condition which, in the opinion of a physician, would make the participant unsuitable for enrollment or could interfere with the participant participating in and completing the trial.
- •Participant who had a life-threatening serious adverse event during the screening period.
- •A participant must not be a member or a family member of the personnel of the investigational or sponsor staff directly involved with this trial.
- •Protocol-specified hematologic, biochemical, and serologic criteria (growth factors may not be used to achieve trial entry requirements).
- •Serum albumin below the lower limit of normal (LLN) of laboratory reference range.
- •Thyroid-stimulating hormone (TSH) >1.2 x Upper Limit of Normal (ULN) or <0.8 x LLN of laboratory reference.
- •Serum creatinine >ULN of the laboratory reference.
- •Protocol-specified serum glucose concentrations.
- •Prothrombin time/partial thromboplastin time (PT/PTT) values >10% above laboratory reference range.
- •Protocol-specified alpha fetoprotein concentrations.
研究组 & 干预措施
Treated/Not Randomized
Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained >10 g/dL throughout the 28- or 48-week treatment period.
干预措施: Boceprevir (Drug)
Treated/Not Randomized
Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained >10 g/dL throughout the 28- or 48-week treatment period.
干预措施: Peginterferon alfa-2b (PEG2b) (Drug)
Treated/Not Randomized
Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained >10 g/dL throughout the 28- or 48-week treatment period.
干预措施: Ribavirin (RBV) (Drug)
Ribavirin Dose Reduction
After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.
干预措施: Boceprevir (Drug)
Ribavirin Dose Reduction
After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.
干预措施: Peginterferon alfa-2b (PEG2b) (Drug)
Ribavirin Dose Reduction
After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.
干预措施: Ribavirin (RBV) (Drug)
Erythropoietin Use
After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.
干预措施: Boceprevir (Drug)
Erythropoietin Use
After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.
干预措施: Peginterferon alfa-2b (PEG2b) (Drug)
Erythropoietin Use
After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.
干预措施: Ribavirin (RBV) (Drug)
Erythropoietin Use
After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.
干预措施: Erythropoietin (Drug)
结局指标
主要结局
Percentage of Participants With Sustained Virologic Response (SVR)
时间窗: At Follow-up Week 24
SVR was defined as undetectable plasma Hepatitis C Virus ribonucleic acid (HCV-RNA) at Follow-up Week 24
次要结局
- Percentage of Participants Who Discontinued Treatment(From Study Day 1 up to Study Treatment Week 48)